Dear Fellow Investor,
There's no sector poised to deliver bigger gains in 2021 than small-cap biotech stocks.
In the past year alone...
- Novavax Inc jumped from $6.26 to $270.51, a gain of 3,396%.
- Aclaris Therapts jumped from $0.70 to $24.28 an increase of 1,583%.
- Vaxart Inc rocketed from $0.97 to $14.94, a 1,083% jump.
What drives massive gains like that?
It usually comes when a biotech unveils a unique new drug.
On December 5, 2020, a small Cambridge biotech shocked the world when they could "Find & Replace" the genes that cause the disease anemia.
This revolutionary new kind of treatment may not just change sickle cell anemia -
It has the potential to eliminate genetic disease from our species.
If that sounds like science fiction, consider this -
- The Nobel Prize Committee is calling it "The Holy Grail of Medicine."
- The Wall Street Journal reports the company is "transforming medicine."
- 60 Minutes reports the company is "revolutionizing the search for new drugs."
Investor's Business Daily estimates the market is worth at least $75 billion. But right now, its stock price is just a tiny fraction of that size.
That's if the company doesn't get taken over for fast 300% gains first.
Sincerely,
Dylan Jovine
Chairman
Behind the Markets
No comments:
Post a Comment